Body iron stores and glucose intolerance in premenopausal women: Role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism

Diabetes Care

Volumn 32, Issue 8, 2009, Pages 1525-1530

  Martínez García, M Ángeles ^a,b   Luque Ramírez, Manuel ^a,b   San Milĺan, Jośe L ^a,b   Escobar Morreale, H́ector F ^a,b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ASPARTIC ACID; C REACTIVE PROTEIN; CYSTEINE; FERRITIN; GLUCOSE; HAPTOGLOBIN; HISTIDINE; INSULIN; IRON; TESTOSTERONE; TYROSINE;

ADULT; ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; GENE; GENETIC VARIABILITY; GENOTYPE; GLUCOSE INTOLERANCE; HFE GENE; HUMAN; HYPERANDROGENISM; IL6 GENE; IL6RALPHA GENE; IL6ST GENE; INFLAMMATION; INSULIN RESISTANCE; IRON METABOLISM; IRON STORAGE; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; NUCLEOTIDE SEQUENCE; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PON1 GENE; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; TNFALPHA GENE; TNFRSF1B GENE; WAIST HIP RATIO;

ADULT; ARYLDIALKYLPHOSPHATASE; BODY MASS INDEX; DNA; EXONS; FEMALE; FERRITINS; GENETIC VARIATION; GLUCOSE INTOLERANCE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; IRON; MENSTRUAL CYCLE; OBESITY; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; PREMENOPAUSE; REFERENCE VALUES; STAT6 TRANSCRIPTION FACTOR;

EID: 68149131547     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-0420     Document Type: Article

References (25)

1. Tuomainen TP, Nyyssonen K, Salonen R, Tervahauta A, Korpela H, Lakka T, Kaplan GA, Salonen JT. Body iron stores are associated with serum insulin and blood glucose concentrations: population study in 1,013 eastern Finnish men. Diabetes Care 1997;20:426-428 (Pubitemid 27098236)
2. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002;51: 2348-2354
3. Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Sanchon R, San Millan JL, Escobar-Morreale HF. The increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism, and do not result from reduced menstrual losses. Diabetes Care 2007;30:2309-2313 (Pubitemid 47359039)
4. Hirayama M, Kohgo Y, Kondo H, Shintani N, Fujikawa K, Sasaki K, Kato J, Niitsu Y. Regulation of iron metabolism in HepG2 cells: a possible role for cytokines in the hepatic deposition of iron. Hepatology 1993;18:874-880
5. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27: 2422-2428 (Pubitemid 39281396)
6. Escobar-Morreale HF, Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Sancho J, San Millan JL. Body iron stores are increased in overweight and obese women with polycystic ovary syndrome. Diabetes Care 2005;28:2042-2044 (Pubitemid 41060986)
7. Botella-Carretero JI, Luque-Ramirez M, Alvarez-Blasco F, San Millan JL, Escobar-Morreale HF. Mutations in the hereditary hemochromatosis gene are not associated with the increased body iron stores observed in overweight and obese women with polycystic ovary syndrome. Diabetes Care 2006;29:2556 (Pubitemid 44912227)
8. Dymock IW, Cassar J, Pyke DA, Oakley WG, Williams R. Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis. Am J Med 1972;52:203-210
9. Escobar-Morreale HF, Sanchon R, San Millan JL. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008;93: 527-533 (Pubitemid 351240826)
10. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In Polycystic ovary syndrome. Dunaif A, Givens JR, Haseltine FP, Merriam GR, Eds. Boston, Blackwell Scientific Publications, 1992, p. 377-384
11. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47
12. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-4245 (Pubitemid 44833391)
13. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470 (Pubitemid 29418240)
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31(Suppl. 1):S55-S60
15. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millan JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res 2003;11:987-996 (Pubitemid 41137511)
16. Escobar-Morreale HF, Calvo RM, Sancho J, San Millán JL. TNF-α and hyperandrogenism: a clinical, biochemical and molecular genetic study. J Clin Endocrinol Metab 2001;86:3761-3767 (Pubitemid 32755973)
17. Peral B, San Millan JL, Castello R, Moghetti P, Escobar-Morreale HF. The methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab 2002; 87:3977-3983 (Pubitemid 34879557)
18. Villuendas G, San Millan JL, Sancho J, Escobar-Morreale HF. The -597 G/A and -174 G/C polymorphisms in the promoter of the interleukin 6 gene (IL6) are associated with hyperandrogenism. J Clin Endocrinol Metab 2002;87:1134-1141 (Pubitemid 36121078)
19. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004;89:2640-2646 (Pubitemid 38766343)
20. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51:1000-1004 (Pubitemid 34438342)
21. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion. Clin Chem 2005;51:1201-1205 (Pubitemid 43079398)
22. McCarty MF. Hyperinsulinemia may boost both hematocrit and iron absorption by up-regulating activity of hypoxiainducible factor-1α. Med Hypotheses 2003;61:567-573
23. Le Guenno G, Chanseaume E, Ruivard M, Morio B, Mazur A. Study of iron metabolism disturbances in an animal model of insulin resistance. Diabetes Res Clin Pract 2007;77:363-370 (Pubitemid 47211345)
24. Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther 2006;80: 105-114 (Pubitemid 44164408)
25. Tomatsu S, Orii KO, Fleming RE, Holden CC, Waheed A, Britton RS, Gutierrez MA, Velez-Castrillon S, Bacon BR, Sly WS. Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. Proc Natl Acad Sci U S A 2003;100: 15788-15793 (Pubitemid 38021068)